103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB4450

 

Introduced 1/16/2024, by Rep. Jackie Haas

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/208  from Ch. 56 1/2, par. 1208

    Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance.


LRB103 36645 RLC 66754 b

 

 

A BILL FOR

 

HB4450LRB103 36645 RLC 66754 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Section 208 as follows:
 
6    (720 ILCS 570/208)  (from Ch. 56 1/2, par. 1208)
7    Sec. 208. (a) The controlled substances listed in this
8Section are included in Schedule III.
9    (b) Unless specifically excepted or unless listed in
10another schedule, any material, compound, mixture, or
11preparation which contains any quantity of the following
12substances having a stimulant effect on the central nervous
13system, including its salts, isomers (whether optical
14position, or geometric), and salts of such isomers whenever
15the existence of such salts, isomers, and salts of isomers is
16possible within the specific chemical designation;
17        (1) Those compounds, mixtures, or preparations in
18    dosage unit form containing any stimulant substances
19    listed in Schedule II which compounds, mixtures, or
20    preparations were listed on August 25, 1971, as excepted
21    compounds under Title 21, Code of Federal Regulations,
22    Section 308.32, and any other drug of the quantitative
23    composition shown in that list for those drugs or which is

 

 

HB4450- 2 -LRB103 36645 RLC 66754 b

1    the same except that it contains a lesser quantity of
2    controlled substances;
3        (2) Benzphetamine;
4        (3) Chlorphentermine;
5        (4) Clortermine;
6        (5) Phendimetrazine.
7    (c) Unless specifically excepted or unless listed in
8another schedule, any material, compound, mixture, or
9preparation which contains any quantity of the following
10substances having a potential for abuse associated with a
11depressant effect on the central nervous system:
12        (1) Any compound, mixture, or preparation containing
13    amobarbital, secobarbital, pentobarbital or any salt
14    thereof and one or more other active medicinal ingredients
15    which are not listed in any schedule;
16        (2) Any suppository dosage form containing
17    amobarbital, secobarbital, pentobarbital or any salt of
18    any of these drugs and approved by the Federal Food and
19    Drug Administration for marketing only as a suppository;
20        (3) Any substance which contains any quantity of a
21    derivative of barbituric acid, or any salt thereof:
22        (3.1) Aprobarbital;
23        (3.2) Butabarbital (secbutabarbital);
24        (3.3) Butalbital;
25        (3.4) Butobarbital (butethal);
26        (4) Chlorhexadol;

 

 

HB4450- 3 -LRB103 36645 RLC 66754 b

1        (5) Methyprylon;
2        (6) Sulfondiethylmethane;
3        (7) Sulfonethylmethane;
4        (8) Sulfonmethane;
5        (9) Lysergic acid;
6        (10) Lysergic acid amide;
7        (10.1) Tiletamine or zolazepam or both, or any salt of
8    either of them.
9    Some trade or other names for a tiletamine-zolazepam
10    combination product: Telazol.
11    Some trade or other names for Tiletamine:
12    2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
13    Some trade or other names for zolazepam:
14    4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
15    [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon.
16        (11) Any material, compound, mixture or preparation
17    containing not more than 12.5 milligrams of pentazocine or
18    any of its salts, per 325 milligrams of aspirin;
19        (12) Any material, compound, mixture or preparation
20    containing not more than 12.5 milligrams of pentazocine or
21    any of its salts, per 325 milligrams of acetaminophen;
22        (13) Any material, compound, mixture or preparation
23    containing not more than 50 milligrams of pentazocine or
24    any of its salts plus naloxone HCl USP 0.5 milligrams, per
25    dosage unit;
26        (14) Ketamine;

 

 

HB4450- 4 -LRB103 36645 RLC 66754 b

1        (15) Thiopental; .
2        (16) Xylazine: (N-2,6-dimethylpheny1)-5,6-
3    dihydro-4H-1,3 thiazin-2-amine), including its isomers,
4    esters, ethers, salts, and salts of isomers, esters, and
5    ethers, whenever the existence of such isomers, esters,
6    ethers, and salts is possible within the specific chemical
7    designation.
8    (d) Nalorphine.
9    (d.5) Buprenorphine.
10    (e) Unless specifically excepted or unless listed in
11another schedule, any material, compound, mixture, or
12preparation containing limited quantities of any of the
13following narcotic drugs, or their salts calculated as the
14free anhydrous base or alkaloid, as set forth below:
15        (1) not more than 1.8 grams of codeine per 100
16    milliliters or not more than 90 milligrams per dosage
17    unit, with an equal or greater quantity of an isoquinoline
18    alkaloid of opium;
19        (2) not more than 1.8 grams of codeine per 100
20    milliliters or not more than 90 milligrams per dosage
21    unit, with one or more active non-narcotic ingredients in
22    recognized therapeutic amounts;
23        (3) (blank);
24        (4) (blank);
25        (5) not more than 1.8 grams of dihydrocodeine per 100
26    milliliters or not more than 90 milligrams per dosage

 

 

HB4450- 5 -LRB103 36645 RLC 66754 b

1    unit, with one or more active, non-narcotic ingredients in
2    recognized therapeutic amounts;
3        (6) not more than 300 milligrams of ethylmorphine per
4    100 milliliters or not more than 15 milligrams per dosage
5    unit, with one or more active, non-narcotic ingredients in
6    recognized therapeutic amounts;
7        (7) not more than 500 milligrams of opium per 100
8    milliliters or per 100 grams, or not more than 25
9    milligrams per dosage unit, with one or more active,
10    non-narcotic ingredients in recognized therapeutic
11    amounts;
12        (8) not more than 50 milligrams of morphine per 100
13    milliliters or per 100 grams with one or more active,
14    non-narcotic ingredients in recognized therapeutic
15    amounts.
16    (f) Anabolic steroids, except the following anabolic
17steroids that are exempt:
18        (1) Androgyn L.A.;
19        (2) Andro-Estro 90-4;
20        (3) depANDROGYN;
21        (4) DEPO-T.E.;
22        (5) depTESTROGEN;
23        (6) Duomone;
24        (7) DURATESTRIN;
25        (8) DUO-SPAN II;
26        (9) Estratest;

 

 

HB4450- 6 -LRB103 36645 RLC 66754 b

1        (10) Estratest H.S.;
2        (11) PAN ESTRA TEST;
3        (12) Premarin with Methyltestosterone;
4        (13) TEST-ESTRO Cypionates;
5        (14) Testosterone Cyp 50 Estradiol Cyp 2;
6        (15) Testosterone Cypionate-Estradiol Cypionate
7    injection; and
8        (16) Testosterone Enanthate-Estradiol Valerate
9    injection.
10    (g) Hallucinogenic substances.
11        (1) Dronabinol (synthetic) in sesame oil and
12    encapsulated in a soft gelatin capsule in a U.S. Food and
13    Drug Administration approved product. Some other names for
14    dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-
15    6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or
16    (-)-delta-9-(trans)-tetrahydrocannabinol.
17        (2) (Reserved).
18    (h) The Department may except by rule any compound,
19mixture, or preparation containing any stimulant or depressant
20substance listed in subsection (b) from the application of all
21or any part of this Act if the compound, mixture, or
22preparation contains one or more active medicinal ingredients
23not having a stimulant or depressant effect on the central
24nervous system, and if the admixtures are included therein in
25combinations, quantity, proportion, or concentration that
26vitiate the potential for abuse of the substances which have a

 

 

HB4450- 7 -LRB103 36645 RLC 66754 b

1stimulant or depressant effect on the central nervous system.
2(Source: P.A. 100-368, eff. 1-1-18.)